Search

Negar Living Sadrzadeh

from Los Altos, CA
Age ~54
Get Report
Also known as:
Negar Te Sadrzadeh, Negar H
Phone and address:
1210 Larnel Pl, Los Altos, CA 94024
(650) 965-8436
Related to:
Negin HaghipourMegan E Sadrzadeh, 43Christa N Heckman, 43Mojgan S Rafiei, 46Naz Sadrzadeh, 46Nader R Sadrzadeh, 51Ali R SadrzadehMartha A Alsleben, 70Mahdieh Sadrzadeh, 50
Connected to:
Arlinda G Sadsarin, 53Mark Sadsarin, 67Sean D Sadtler, 47Bharat Sadula, 45Ina V Sadulski, 72Esteban Sadurni, 63Jose M Sadurni, 84Julie Sadus, 44David F Sadvar, 66Timothy M Sadwick, 59

Negar Sadrzadeh Phones & Addresses

  • 1210 Larnel Pl, Los Altos, CA 94024 (650) 965-8436
  • 1104 Royal Ln, San Carlos, CA 94070 (650) 654-8930
  • 150 Industrial Rd, San Carlos, CA 94070
  • 114 Woodbury Ln, Lake Bluff, IL 60044
  • 309 Everglade Dr, Madison, WI 53717 (608) 833-6333
  • Santa Clara, CA
  • Tulare, CA
  • San Mateo, CA
  • Lindsay, CA
  • 1210 Larnel Pl, Los Altos, CA 94024 (650) 654-8930

Work

Company: Map pharmaceuticals - Mountain View, CA Dec 2009 Position: Senior cmc manager/ventures program director

Education

School / High School: University of Wisconsin-Madison- Madison, WI 1997 Specialities: Ph.D. in Pharmaceutical Chemistry

Resumes

Resumes

Negar Sadrzadeh Photo 1

Negar Sadrzadeh

View page
Negar Sadrzadeh Photo 2

Negar Sadrzadeh San Carlos, CA

View page
Work:
MAP Pharmaceuticals
Mountain View, CA
Dec 2009 to Feb 2012
Senior CMC Manager/Ventures Program Director
Anesiva, Inc.
South San Francisco, CA
Jan 2009 to Aug 2009
Independent Consultant
Anesiva, Inc
South San Francisco, CA
2007 to 2008
Director, Pharmaceutical Development
Nektar Therapeutics
San Carlos, CA
Jun 1999 to May 2007
Associate Director
Abbott Laboratories
North Chicago, IL
1997 to 1999
Research Scientist
Education:
University of Wisconsin-Madison
Madison, WI
1997
Ph.D. in Pharmaceutical Chemistry
University of Wisconsin
Madison, WI
1989 to 1991
BS in Chemistry and French
Bryn Mawr College
Bryn Mawr, PA
1987 to 1989

Publications

Us Patents

Sustained Release Compositions For Delivery Of Pharmaceutical Proteins

View page
US Patent:
20050203002, Sep 15, 2005
Filed:
Jan 7, 2005
Appl. No.:
11/031031
Inventors:
Stelios Tzannis - Newark CA, US
Nancy Dasovich - San Francisco CA, US
Sandeep Kumar - Thousand Oaks CA, US
Negar Sadrzadeh - San Carlos CA, US
International Classification:
A61K038/28
A61L009/04
A61K009/14
US Classification:
514004000, 424046000
Abstract:
The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.

Sustained Release Microparticles For Pulmonary Delivery

View page
US Patent:
20070031342, Feb 8, 2007
Filed:
May 9, 2006
Appl. No.:
11/430665
Inventors:
Stelios Tzannis - Newark CA, US
Negar Sadrzadeh - San Carlos CA, US
Helen Schiavone - Freeland WA, US
Renee Labiris - Paris, CA
International Classification:
A61L 9/04
A61K 38/23
A61K 31/573
US Classification:
424045000, 514012000, 514171000, 977906000
Abstract:
A composition of microparticles for delivery to the pulmonary system provides sustained release of a pharmaceutical agent. The microparticles comprise a lipid structural matrix comprising a multilamellar structure of lipid bilayers having lipid chains ordered in an Lphase. The lipid matrix at least partially encapsulates the pharmaceutical agent at a bilayer interface formed between head groups of adjacent lipid layers. The microparticles are prepared by heating a precursor formulation comprising a solvent, matrix-forming excipient and pharmaceutical agent to a temperature above the liquid-crystalline transition temperature Tof the matrix-forming excipient and below the melting or denaturation point of the pharmaceutical agent. The solvent is then removed to form microparticles with partially encapsulated pharmaceutical agent.

Sustained Release Compositions For Delivery Of Pharmaceutical Proteins

View page
US Patent:
20080031966, Feb 7, 2008
Filed:
Feb 7, 2007
Appl. No.:
11/703553
Inventors:
Stelios Tzannis - Newark CA, US
Nancy Dasovich - San Francisco CA, US
Sandeep Kumar - Thousand Oaks CA, US
Negar Sadrzadeh - San Carlos CA, US
International Classification:
A61K 9/52
A61P 3/10
US Classification:
424499000
Abstract:
The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.
Control profile
Negar Living Sadrzadeh from Los Altos, CA, age ~54 Get Report